74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ironwood Pharmaceuticals Inc
Closed
Sector Healthcare
1.81 -5.73
Overview
Share price change
24h
Min
1.78
Max
1.81
Income | 4.5M 3.6M |
|---|---|
Sales | -2.8M 92M |
P/E Sector Avg | 51.5 73.394 |
EPS | 0.02 |
Profit margin | 3.981 |
Employees | 267 |
EBITDA | 443K 27M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +383.52 upside |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | -56M 310M |
|---|---|
Previous open | 7.54 |
Previous close | 1.81 |
News Sentiment
By Acuity
10%
90%
8 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Ironwood Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ironwood Pharmaceuticals Inc Forecast
Price Target
By TipRanks
383.52% upside
12 Months Forecast
Average 8.8 USD 383.52%
High 14 USD
Low 4 USD
Based on 5 Wall Street analysts offering 12 month price targets forIronwood Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
8 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
